Misiu and Chuckles' colleague family can help us out further by putting on a scientist hat and getting as much patient-specific data as possible from these anecdotes, that can try nail down the connection to LL in their road to recovery. Misu can ask our management whether and how she can help in this regard, within the bounds of Right-to-Try.
For example, can we get blood samples of the patients from before and after Leronlimab was administered, for bio-marker analysis? Probably we already missed the chance to do this for before LL; but even now we can monitor the progress over the next couple of weeks.
If such is not possible, they can still jot down the small details of the patient's struggles before and day-by-day recovery after LL was given, along with the general characteristics of the patient like age, comorbidities, vaccination status, and anything else that will give us insight into why they may have gone into critical stage and why Leronlimab was likely the key cause for their recovery and how it may have made this difference. The monitoring doctor's affirmation in this regard will also be important.
These anecdotes resemble some of the early eINDs that showed dramatic impact of Leronlimab within a very short time. The recovery of oxygen levels is something we heard often. We also got such ideas from Estrada camp initially, of the 'wonder drug', but then silence thereafter - as if they dared not speak out specifically for LL later. Yet we know that not everyone had such miraculous recovery and in so short a time. Or they relapsed later due to lack of repeat dosage and that had masked the initial effect of LL. Even with Marksch's wife, I don't think the change was this stark and swift. What possibly made our patients specially suited to LL?
So, we have opportunity to build a proper data-based analysis and a bias-free scientific case for these patients who seem to be recovering because of LL and who are close to our forum members.
AI
Market Data 
Markets 
